Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of immunotherapy products for the treatment of cancer, with its primary focus on preventing breast cancer recurrence through its lead product candidate, GLSI-100.

The company generates revenue primarily through potential future commercialization of its product candidates, as it currently does not have any products approved for sale and is not generating revenue from product sales; its current activities are centered on clinical development and research.

The company operates through a single reportable segment focused on the research, development, and potential commercialization of its immunotherapy product candidates.

• Greenwich LifeSciences, Inc. focuses its operations on the development of GLSI-100, which consists of the GP2 peptide combined with the immunoadjuvant GM-CSF, designed to elicit a targeted immune response against HER2/neu-expressing cancers, particularly for the prevention of breast cancer recurrence in patients who have completed standard trastuzumab-based therapy.

Greenwich LifeSciences, Inc. operates in the competitive field of cancer immunotherapy, where it faces large pharmaceutical companies with approved products and substantial resources, but believes its product candidate may offer a differentiated approach by targeting the HER2/neu antigen in combination with GM-CSF to stimulate a durable immune response in a specific patient population.

The company serves patients with HER2/neu-positive breast cancer who are at high risk of recurrence following surgery and standard adjuvant therapy, with its product candidate intended for use in clinical and hospital settings under physician supervision.